EMBC logo

EMBECTA CORP

EMBCNASDAQ
🏆 #3249 by market capEarnings Nov 23 · PreUS Equity
$5.76▼ $0.17 (−3.03%)
Market closed · at close
🔔
Track EMBC
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.0%
7d▲ 3.0%
14d▲ 12.3%
30d▲ 11.8%
ytd▼ 51.6%
1y▼ 59.1%
🏦Market Cap
$342M
Small Cap
📈Revenue Growth (YoY)
-3.8%
Declining
📊Gross Margin
59.9%
Healthy
💵FCF Margin
16.2%
Healthy
⚖️P/S Ratio
0.3x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$5.69 – $5.87
52-Week Range
$2.77 – $14.91
Volume
$2.71B
Avg Volume
$3.02B
Shares Outstanding
59.3M
Next Earnings
Dec 11, 2026

Fundamentals Snapshot

Annual Revenue
$1.08B
Last Q Revenue
$272M
P/E Ratio
4.0
P/S Ratio
0.3x
EPS (TTM)
$1.50
Dividend Yield
5.40%
Dilution (1yr)
+0.5%

Why Investors Own EMBC

  • ✓High-growth profile — revenue up -2.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 52% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EMBC logo

EMBECTA CORP

EMBC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.1B▼ −3.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
62.9%▼ −3.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$329M▲ +89.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$182M▲ +816.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
58.9M▲ +0.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$1.2B▲ +$175M YoY
StockOtter · stockotter.space

About EMBECTA CORP

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$6.87
▲ +19.3% Upside
High Target$8.23
Low Target$5.58
Based on 12 analysts

Latest News & Updates

🚀
CNBC·2h ago

EMBECTA CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift EMBC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

EMBECTA CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.